LY404039是mGluR1和mGluR2的抑制剂,Ki分别为149 nM和92 nM,还能抑制多巴胺受体。
LY404039 is a potent agonist of recombinant human mGlu2/mGlu3 receptors with Ki of 149 nM/92 nM, shows >100-fold selectivity over ionotropic glutamate receptors, glutamate transporters, and other receptors. Phase 3.
10 mg/kg 腹腔注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Rorick-Kehn LM et al. J Pharmacol Exp Ther, 2007, 321(1), 308-317.
分子式 C7H9NO6S |
分子量 235.21 |
CAS号 635318-11-5 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 1 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01637142 | Healthy Participants | Drug: LY2140023|Drug: 14C-LY2140023|Drug: 14C-LY404039 | Eli Lilly and Company | Phase 1 | 2012-07-01 | 2012-08-09 |
NCT01440478 | Healthy Subjects | Drug: LY2140023|Drug: Ammonium chloride|Drug: Sodium bicarbonate | Eli Lilly and Company | Phase 1 | 2011-09-01 | 2011-10-07 |
NCT01659177 | Healthy Participants | Drug: LY2140023 | Eli Lilly and Company | Phase 1 | 2012-08-01 | 2012-09-28 |
NCT01475136 | Hepatic Insufficiency | Drug: LY2140023 | Eli Lilly and Company | Phase 1 | 2011-11-01 | 2013-01-10 |
NCT01591330 | Healthy Volunteers | Drug: LY2140023 Monohydrate (Reference)|Drug: LY2140023 Monohydrate (Test - Low)|Drug: LY2140023 Monohydrate (Test - Medium)|Drug: LY2140023 Monohydrate (Test - High) | Eli Lilly and Company | Phase 1 | 2012-04-01 | 2012-07-02 |
NCT01609218 | Healthy Volunteer Study | Drug: LY2140023|Drug: Aqueous activated charcoal | Eli Lilly and Company | Phase 1 | 2012-05-01 | 2012-10-04 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们